Anzeige
Meldung des Tages: Ist das DIE Rohstoff-Story des Jahres?

Armata Pharmaceuticals Aktie News

Aktie
WKN:  A2PKLC ISIN:  US04216R1023 US-Symbol:  ARMP Branche:  Biotechnologie Land:  USA
5,30 €
+0,1 €
+1,92%
22:13:00 Uhr
Depot/Watchlist
Marktkapitalisierung *
202,23 Mio. €
Streubesitz
28,77%
KGV
-4,13
Index-Zuordnung
-

Armata Pharmaceuticals News

13.01.26 - PR Newswire
/C O R R E C T I O N -- Armata Pharmaceuticals, Inc./
/C O R R E C T I O N -- Armata Pharmaceuticals, Inc./ PR Newswire
18.11.25 - PR Newswire
Armata Pharmaceuticals Announces Key Opinion Leader Webinar on S. aureus Bacteremia and AP-SA02 Hosted by Jones Research on November 25th at 10:00am EST
Armata Pharmaceuticals Announces Key Opinion Leader Webinar on S. aureus Bacteremia and AP-SA02 Hosted by Jones Research on November 25th at 10:00am EST PR Newswire
12.11.25 - PR Newswire
Armata Pharmaceuticals Announces Third Quarter 2025 Results and Provides Corporate Update
Armata Pharmaceuticals Announces Third Quarter 2025 Results and Provides Corporate Update PR Newswire
10.11.25 - PR Newswire
Armata Pharmaceuticals Announces Formal Commissioning of State-of-the-Art cGMP Phage Manufacturing Facility in Los Angeles, California
Armata Pharmaceuticals Announces Formal Commissioning of State-​of-the-Art cGMP Phage Manufacturing Facility in Los Angeles, California PR Newswire
22.10.25 - PR Newswire
Armata Pharmaceuticals Highlights Positive Results from Phase 2a diSArm Study of its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, in Late-Breaking Oral Presentation at IDWeek 2025™
Armata Pharmaceuticals Highlights Positive Results from Phase 2a diSArm Study of its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, in Late-​Breaking Oral ...
14.10.25 - PR Newswire
Armata Pharmaceuticals to Present Late-Breaking Clinical Data highlighting its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, at IDWeek 2025™
Armata Pharmaceuticals to Present Late-​Breaking Clinical Data highlighting its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, at IDWeek 2025™ PR Newswire
08.09.25 - PR Newswire
Armata Pharmaceuticals Announces Structural Biology Publication in the Journal of Molecular Biology
Armata Pharmaceuticals Announces Structural Biology Publication in the Journal of Molecular Biology PR Newswire
04.09.25 - PR Newswire
Armata Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Armata Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference PR Newswire
12.08.25 - PR Newswire
Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update
Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update PR Newswire
19.05.25 - PR Newswire
Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia
Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus ...
14.05.25 - PR Newswire
Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update
Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update PR Newswire
01.05.25 - PR Newswire
Armata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02
Armata Pharmaceuticals Receives $4.65 Million of Additional Non-​Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02 ...
20.03.25 - PR Newswire
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Results and Provides Corporate Update
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Results and Provides Corporate Update PR Newswire
12.03.25 - PR Newswire
Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva
Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva PR Newswire
11.03.25 - PR Newswire
Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 7th Annual Bacteriophage Therapy Summit
Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 7th Annual Bacteriophage Therapy Summit PR Newswire

Newssuche

Videos

newspaper
21:20 Uhr -33,33%
Trading Insights vom 22.01.26
Preisschock bei Erdgas! Was sind die Gründe, wie geht man damit um? Gold auf neuem Allzeithoch: wie ... Mehr »